Bristol, UK — Tocris Bioscience, part of the Biotechnology division of Bio-Techne, has launched a new range of fluorescent dyes, known as Janelia Fluor™ dyes, for advanced imaging techniques. The molecules were developed by Luke Lavis’ lab at the Janelia Research Campus and have been licensed to Tocris by the Howard Hughes Medical Institute (HHMI).

The range comprises Janelia Fluor™ dyes JF646 and JF549 and photoactivatable derivatives of these reagents. The new dyes are rhodamine-based and are brighter and more photostable than currently available products. They are also cell-permeable and are supplied a NHS esters for ease of conjugation to antibodies and other proteins. To date Janelia Fluor™ dyes have been used in super resolution microscopy, including dSTORM, single molecule tracking in cells, confocal fluorescent imaging and are also suitable for multiplexing. Tocris Product Manager, Hannah Maple said, “We are excited to make these innovative new dyes commercially available to the research community. They are widely applicable across a range of advanced imaging techniques and should enable life science researchers to generate enhanced images and accelerate new discoveries.”

For more information on Janelia Fluor™ dyes see, www.tocris.com/janelia

      *  *  *  *  *  *  *  *  *  *  *  *

ABOUT TOCRIS BIOSCIENCE
Tocris Bioscience is part of the Biotechnology division of Bio-Techne. Our goal is to provide the global life science research community with the most innovative and high performing products to enable ground breaking discoveries. From its origins as a supplier of neuroscience research products, Tocris Bioscience has expanded to now offer innovative chemical tools for research in fields such as cancer, epigenetics and stem cells.

ABOUT BIO-TECHNE
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds — which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota. The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls for OEM customer and clinical customers. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $499 million in net sales in fiscal 2016 and has approximately 1,700 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.